Covid 19 Research using Clinical Trials (Home Page)
Report for D000857: Olfaction Disorders NIH
(Synonyms: Olf, Olfaction Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug613 | Physiological serum Wiki | 0.71 |
| drug996 | olfactory and gustatory tests Wiki | 0.71 |
| drug139 | Budesonide Nasal Wiki | 0.71 |
Correlated MeSH Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection
Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.
NCT04354857 COVID-19 Other: olfactory and gustatory tests MeSH:Olfaction Disorders
HPO:Anosmia
Primary Outcomes
Description: Positive/negative according to RT-PCR assay
Measure: SARS-CoV-2 infection status Time: Day 0
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 0
Secondary Outcomes
Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Day 0
Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Six months
Description: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Day 0
Description: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Six months
Description: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Day 0
Description: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Six months
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 7
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 14
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 30
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 60
Description: % patients hospitalized
Measure: Severity of infection according to hospitalization rate Time: End of study (six months)
Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Six months
2 A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
Primary Outcomes
Description: Positive/negative according to RT-PCR assay
Measure: SARS-CoV-2 infection status Time: Day 0Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 0Secondary Outcomes
Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Day 0Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale
Measure: Ability to detect odor Time: Six monthsDescription: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Day 0Description: Ability to taste a pinch of table salt on a 0-100 VAS scale
Measure: Ability to detect salty taste Time: Six monthsDescription: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Day 0Description: Ability to taste a pinch of sugar on a 0-100 VAS scale
Measure: Ability to detect sweet taste Time: Six monthsDescription: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 7Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 14Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 30Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Day 60Description: % patients hospitalized
Measure: Severity of infection according to hospitalization rate Time: End of study (six months)Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)
Measure: Olfactory and gustatory loss Time: Six monthsThe initial symptoms described in the first cases of COVID-19 were mainly fever and respiratory signs. Recently, there has been an increase in cases of hyposmia without associated nasal obstruction or rhinorrhea. Although we do not yet know the long-term consequences of COVID-19 on olfaction, there is evidence in the literature demonstrating that post-viral hyposmias are an important source of long-term olfactory disorders, impacting quality of life. Usually, the treatment of viral hyposmias is based on local and/or general corticosteroid treatment combined with saline nasal irrigation at the onset of signs. Because of the possible development of severe forms of the SARS-Cov-2 infection, the French Society of Otorhinolaryngology has advised against treatment by corticosteroid therapy and nasal irrigation. However, as the virus is present in the nasal fossae on average for 20 days, persistent hyposmia at 30 days would probably result from an inflammatory or neurological damage to the nasal slits or olfactory bulb. Local treatment with corticosteroids could then be instituted from 30 days after the onset of symptoms of COVID-19 without risk of dissemination. In persistent hyposmia other than chronic rhinosinusitis, the only treatment that has proven its efficacy is nasal irrigation associated with budesonide and olfactory rehabilitation. However, this drug does not have marketing authorisation in France for this indication.
NCT04361474 Budesonide Olfaction Disorders SARS-CoV-2 Anosmia Drug: Budesonide Nasal Other: Physiological serum MeSH:Olfaction Disorders
HPO:Anosmia
Primary Outcomes
Description: Percentage of patients with an improvement of more than 2 points on the ODORATEST score (5) after 30 days of treatment
Measure: Patient with more than 2 points on the ODORATEST Time: 30 days
HPO Nodes
HP:0000458: Anosmia
Genes 67
IL17RD PHYH KISS1R OTX2 HESX1 FGFR1 HS6ST1 PEX7 PROKR2 DUSP6 CCDC141 PROK2 MFN2 FGFR1 ANOS1 FGF8 FGFR1 FLRT3 HESX1 ADCY3 SMCHD1 CHD7 SEMA3A TAC3 NSMF PEX7 ARSL PROKR2 SOX10 SMCHD1 GNRH1 SCN9A WDR11 DNAI1 IL17RD SPRY4 FEZF1 SEMA3E KISS1 ANK1 TACR3 CHD7 PHYH SEMA3E SHH SOX10 DCC ANOS1 CHD7 NSMF SOX10 SOX3 WDR11 PROKR2 PEX7 SEMA3A FEZF1 ARNT2 FGF17 KISS1R SOX10 CCDC141 PROK2 ATP13A2 CHD7 FGF8 SOX2 Protein Mutations 0
SNP 0
Primary Outcomes
Description: Percentage of patients with an improvement of more than 2 points on the ODORATEST score (5) after 30 days of treatment
Measure: Patient with more than 2 points on the ODORATEST Time: 30 days